{Reference Type}: Journal Article
{Title}: [Management of patients with metastatic cutaneous melanoma: French national guidelines. French National Cancer Institute].
{Author}: Leccia MT;Planchamp F;Sassolas B;Combemale P;Modiano P;Bedane C;Cupissol D;Derrey S;Dygai-Cochet I;Lamant L;Lubrano V;Mirabel X;Mourrégot A;Rougé Bugat ME;Siegrist S;Thariat J;Tiffet O;Truc G;Verdoni L;Mazeau-Woynar V;
{Journal}: Ann Dermatol Venereol
{Volume}: 141
{Issue}: 2
{Year}: Feb 2014
{Factor}: 0.934
{DOI}: 10.1016/j.annder.2013.10.055
{Abstract}: <B>BACKGROUND: </B>Recent years have seen the emergence of new molecules for the treatment of patients with metastatic cutaneous melanoma, with significant benefits in terms of survival and the opening of new therapeutic perspectives. In addition, many techniques are currently being developed for locoregional treatment of metastatic sites. Management of metastatic melanoma is thus fast-changing and is marked by innovative therapeutic approaches. However, the availability of these new treatments has prompted debate among healthcare professionals concerning their use and their place in therapeutic strategy.<BR><B>OBJECTIVE: </B>Since 2008, the French National Cancer Institute (INCa) has been leading a project to define and diffuse national clinical practice guidelines. It has performed a review of these treatment methods, which it aims to circulate, and it is seeking to develop recommendations in order to allow nationwide implementation of innovative approaches while promoting good use thereof.<BR><B>METHODS: </B>The clinical practice guidelines development process is based on systematic literature review and critical appraisal by experts within a multidisciplinary working group, with feedback from specialists in cancer care delivery. The recommendations are thus based on the best available evidence and expert agreement. Prior to publication, the guidelines are reviewed by independent practitioners in cancer care delivery.<BR><B>RESULTS: </B>This article presents the national recommendations for first- and second-line systemic treatment and for locoregional treatment of metastatic sites in patients presenting metastatic cutaneous melanoma.